IBRX

Business Context and Reporting Period

Company: ImmunityBio, Inc. (IBRX)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: ImmunityBio is a biotechnology company focused on developing next-generation immunotherapies, primarily anchored by its lead product, ANKTIVA (nogapendekin alfa inbakicept), an IL-15 receptor superagonist. The company operates in a single segment focused on oncology and infectious diseases. As of the reporting date, ANKTIVA is approved in the U.S., UK, Saudi Arabia, and the EU (conditional) for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). It also holds conditional approval in Saudi Arabia for metastatic non-small cell lung cancer (NSCLC).

Key Financial Metrics

Note: The company reported a net loss of $351.5 million for 2025, driven primarily by significant research and development expenses ($218.6 million) and interest expenses related to related-party debt and revenue interest liabilities. Revenue growth was driven by the commercialization of ANKTIVA, which began in May 2024.

Material Changes vs. Prior Period

• Revenue Surge: Net product revenue increased by approximately 700% year-over-year, reaching $113 million, driven by the commercial launch of ANKTIVA in the U.S. and initial international sales.
• Regulatory Milestones:
  • Received conditional marketing authorization from the European Commission (EMA) for ANKTIVA in NMIBC (February 2026).
  • Received conditional approval from the Saudi Food and Drug Authority (SFDA) for ANKTIVA in combination with checkpoint inhibitors for metastatic NSCLC (January 2026).
  • Received approval from the UK MHRA for ANKTIVA in NMIBC (July 2025).
• Capital Structure: The company raised approximately $400.6 million in net proceeds from equity offerings in 2025, including Registered Direct Offerings (RDOs) and At-The-Market (ATM) sales. This increased total liquidity to $242.8 million despite operating cash outflows.
• Debt Obligations: The company maintains a $505 million convertible promissory note held by a related party (Nant Capital) and a revenue interest liability of $324.6 million under the Revenue Interest Purchase Agreement (RIPA) with Oberland.

Guidance, Outlook, and Risks

Outlook and Strategy:

• Commercialization: The company is expanding its commercial infrastructure globally, including partnerships with Accord Healthcare in the EU and Cigalah Healthcare/Biopharma in the Middle East.
• Pipeline Expansion: Seeking to expand ANKTIVA indications to include BCG-naive NMIBC, NSCLC (first-line and second-line), glioblastoma, pancreatic cancer, and lymphopenia reversal. The company is also advancing its CAR-NK and vaccine platforms.
• Manufacturing: Investing in the Dunkirk, NY facility to scale manufacturing capabilities, with a commitment to spend $55 million in capital and operational expenses over a three-year term.

Key Risks and Contingencies:

• Liquidity and Going Concern: The company has a history of operating losses and an accumulated deficit of $3.7 billion. While management believes current cash and potential financing are sufficient for the next 12 months, substantial doubt exists regarding the ability to continue as a going concern without additional funding or financial support.
• Debt Covenants: The RIPA imposes significant payment obligations based on net sales (tiered 4.5% to 10.0%) and includes a "True-Up Payment" mechanism if cumulative payments do not meet thresholds by the Test Date (December 31, 2029). Failure to meet covenants could trigger a Put Option, requiring immediate repayment.
• Regulatory Uncertainty: The FDA issued a "Refusal to File" (RTF) letter in May 2025 regarding the sBLA for ANKTIVA in BCG-unresponsive NMIBC with papillary tumors, requesting additional information. The company submitted requested data in February 2026, but approval is not guaranteed.
• Supply Chain: Commercialization relies on the availability of BCG. The company has an agreement with Serum Institute to supply recombinant BCG (rBCG) to address shortages of TICE BCG.
• Related-Party Transactions: Significant debt and operational agreements exist with entities affiliated with Dr. Patrick Soon-Shiong (Founder/Executive Chairman), including the $505 million promissory note and shared services agreements.

Investor Verification Checklist

• Verify Liquidity Runway: Confirm the sufficiency of the $242.8 million cash position against the $505 million related-party debt maturity (2027) and ongoing RIPA payment obligations.
• Monitor RIPA Terms: Review the specific triggers for the "True-Up Payment" and the Put Option under the Revenue Interest Purchase Agreement, as these could force immediate capital raising.
• Track Regulatory Status: Monitor the FDA's response to the February 2026 data submission regarding the papillary NMIBC indication and the status of the EU conditional marketing authorization post-approval requirements.
• Assess BCG Supply: Verify the progress of the Serum Institute rBCG supply chain and its impact on ANKTIVA sales volume, given the historical shortage of TICE BCG.
• Review Related-Party Debt: Examine the terms of the $505 million convertible note, specifically the conversion price ($5.4270) and the recent amendment allowing partial conversion, to assess potential dilution.
• Check Litigation Status: Monitor the outcome of the arbitration with Shenzhen Beike Biotechnology Co. Ltd. regarding the China license agreement and the SRS/Altor CVR arbitration regarding the missed regulatory milestone.